ENLIVEX THERAP.LTD.IS-,01
ENLIVEX THERAP.LTD.IS-,01/ IL0011319527 /
1BT
|
9/13/2024 8:02:30 AM
|
Chg.
+0.2500
|
Volume |
Bid9:59:42 PM |
Ask9:59:55 PM |
High |
Low |
|
1.4100EUR
|
+21.55%
|
0
Turnover: 0.0000 |
-Bid Size: - |
-Ask Size: - |
1.4100 |
1.4100 |
Business description
The company is focused on macrophage reprogramming, intend to develop and commercialize a drug pipeline for macrophage reprogramming in Sepsis, Osteoarthritis, solid cancers, and other indications. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Management board & Supervisory board
| CEO |
| Oren Hershkovitz |
| Management board |
| Shachar Shlosberger, Prof. Dror Mevorach, Einat Galamidi, Veronique Amor-Baroukh, Iris Tavor, Chen Ankri, Sigal Arad |
| Supervisory board |
| Shai Novik, Dr. Roger Pomerantz, Dr. Brian Schwartz, Abraham Havron, Gili Hart, Andrew Singer |
Company data
| Name: |
Enlivex Therapeutics Ltd. |
| Address: |
14 Einstein St.,Nes-Ziona 7403618 |
| Phone: |
+972.8.6380330 |
| Fax: |
- |
| E-mail: |
info@enlivexpharm.com
|
| Internet: |
https://enlivex.com/ |
| Industry: |
Healthcare |
| Sector: |
Healthcare Providers |
| Sub sector: |
Healthcare Providers |
| End of financial year: |
12/31 |
| Free Float: |
87.17% |
| IPO date: |
12/12/1995 |
Investor relations
| Name: |
- |
| IR phone: |
- |
| IR Fax: |
- |
| IR e-mail: |
-
|
Company calendar
|
CW 44 | 10/31/2024
General Shareholder Meeting
|
